Business
Nanox Announces Fourth Quarter of 2023 Financial Results and Provides Business Update
Nanox Launches Nanox.ARC in United States with Installations Across Five States, Marking a Major Advancement in Medical Imaging Management to host conference
About this update from Nano-x Imaging Ltd
[{"type":"text","content":"Nanox Launches Nanox.ARC in United States with Installations Across Five States, Marking a Major Advancement in Medical Imaging Management to host conference call and webcast Monday, April 1, 2024 at 8:30 AM ET PETAH TIKVA, Israel, April 01, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced results for the fourth quarter ended December 31, 2023 and provided a business update. Fourth Quarter 2023 Highlights and Recent Developments: Generated $2.4 million in revenue in the fourth quarter of 2023, compared to $2.1 million in the fourth quarter of 2022. Made significant progress in US deployment, with multiple Nanox.ARC systems now deployed in 5 states. The Nanox.ARC has begun to scan patients in the U.S. passed all required tests in three states conducted by a licensed and certified physicists. Nanox.AI secured FDA clearance for HealthFLD, an advanced AI-based software empowering clinicians in assessment of fatty liver disease, and which may deliver advantages to the biopharmaceutical industry. InterMountain Health has signed on to deploy HealthCCS and was part of a Nuance bundle. Initial data readout from the ADOPT study, being held at Oxford University Hospital and other locations in the UK, demonstrated a sixfold increase in identifying previously undiagnosed patients with vertebral compression fracture using Nanox.AI’s HealthVCF solution. Began multi-site clinical trial to study the Nanox.ARC use for chest indications. Continued to advance the process of securing CE-mark in the EU “I am incredibly proud to announce another strong quarter and year for Nanox,” said Erez Meltzer, Nanox Chief Executive Officer. “First and foremost, we achieved a pivotal milestone in fiscal year 2023, getting FDA clearance for the Nanox ARC systems and deploying them in the key US market. With significant regulatory successes in hand, Nanox is committed to accelerating the execution of our commercial infrastructure and strategic plans in the US. Our mission is to provide healthcare practices with a transformative advantage through the Nanox.ARC – an accessible, end-to-end, and cost-effective solution that not only provides advanced diagnostic imaging capabilities but also elevates overall patient care. Additionally, we are constantly advancing our ...